HomeCompareWBK vs ABBV

WBK vs ABBV: Dividend Comparison 2026

WBK yields 226.32% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 WBK wins by $101235.53M in total portfolio value
10 years
WBK
WBK
● Live price
226.32%
Share price
$14.20
Annual div
$32.14
5Y div CAGR
16.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$101235.63M
Annual income
$85,507,150,434.98
Full WBK calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — WBK vs ABBV

📍 WBK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodWBKABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, WBK + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
WBK pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

WBK
Annual income on $10K today (after 15% tax)
$19,237.30/yr
After 10yr DRIP, annual income (after tax)
$72,681,077,869.73/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, WBK beats the other by $72,681,056,813.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of WBK + ABBV for your $10,000?

WBK: 50%ABBV: 50%
100% ABBV50/50100% WBK
Portfolio after 10yr
$50617.87M
Annual income
$42,753,587,603.37/yr
Blended yield
84.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

WBK
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

WBK buys
0
ABBV buys
0
No recent congressional trades found for WBK or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricWBKABBV
Forward yield226.32%3.06%
Annual dividend / share$32.14$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR16.8%40.6%
Portfolio after 10y$101235.63M$102.3K
Annual income after 10y$85,507,150,434.98$24,771.77
Total dividends collected$100012.76M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: WBK vs ABBV ($10,000, DRIP)

YearWBK PortfolioWBK Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$37,134$26,434.31$11,550$430.00+$25.6KWBK
2$146,886$107,152.51$13,472$627.96+$133.4KWBK
3$619,834$462,665.50$15,906$926.08+$603.9KWBK
4$2,794,403$2,131,181.08$19,071$1,382.55+$2.78MWBK
5$13,478,026$10,488,014.23$23,302$2,095.81+$13.45MWBK
6$69,640,615$55,219,127.87$29,150$3,237.93+$69.61MWBK
7$385,963,016$311,447,557.73$37,536$5,121.41+$385.93MWBK
8$2,297,180,805$1,884,200,378.03$50,079$8,338.38+$2297.13MWBK
9$14,699,511,705$12,241,528,242.96$69,753$14,065.80+$14699.44MWBK
10$101,235,627,959$85,507,150,434.98$102,337$24,771.77+$101235.53MWBK

WBK vs ABBV: Complete Analysis 2026

WBKStock

Westpac Banking Corporation provides various banking and financial services in Australia, New Zealand, the Americas, Asia, Europe, and internationally. It offers everyday banking, savings, term deposit, business transaction, foreign currency, and specialized accounts; home, personal, and business loans; credit cards; international and travel services; share trading services; investment; and home, car, travel, life, and business insurance products. The company also provides merchant and payment, corporate and institutional, transaction banking, financial market, corporate and structured finance, trade and supply chain financing, and industry specific banking and treasury services, as well as online banking services. It serves individuals; micro, small, and medium enterprises; commercial business and private wealth clients; and commercial, corporate, institutional, and government customers. The company was formerly known as Bank of New South Wales and changed its name to Westpac Banking Corporation in October 1982. The company was founded in 1817 and is based in Sydney, Australia.

Full WBK Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this WBK vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

WBK vs SCHDWBK vs JEPIWBK vs OWBK vs KOWBK vs MAINWBK vs JNJWBK vs MRKWBK vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.